Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature

Hye Won Lee; Moon Jae Chung; Huapyong Kang; Heun Choi; Youn Jeong Choi; Kyung Joo Lee; Seung Woo Lee; Seung Hyuk Han; Jin Seok Kim; Si Young Song

doi:10.5009/gnl.2014.8.1.109

Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature

Hye Won Lee, Moon Jae Chung, Huapyong Kang, Heun Choi, Youn Jeong Choi, Kyung Joo Lee, Seung Woo Lee, Seung Hyuk Han, Jin Seok Kim, Si Young Song

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

Original language	English
Pages (from-to)	109-112
Number of pages	4
Journal	Gut and liver
Volume	8
Issue number	1
DOIs	https://doi.org/10.5009/gnl.2014.8.1.109
Publication status	Published - 2014 Jan

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5009/gnl.2014.8.1.109

Cite this

@article{dda8c341513f417490e2a55b63836bac,

title = "Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature",

abstract = "Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.",

author = "Lee, {Hye Won} and Chung, {Moon Jae} and Huapyong Kang and Heun Choi and Choi, {Youn Jeong} and Lee, {Kyung Joo} and Lee, {Seung Woo} and Han, {Seung Hyuk} and Kim, {Jin Seok} and Song, {Si Young}",

year = "2014",

month = jan,

doi = "10.5009/gnl.2014.8.1.109",

language = "English",

volume = "8",

pages = "109--112",

journal = "Gut and Liver",

issn = "1976-2283",

publisher = "Joe Bok Chung",

number = "1",

}

TY - JOUR

T1 - Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer

T2 - A case report and review of the literature

AU - Lee, Hye Won

AU - Chung, Moon Jae

AU - Kang, Huapyong

AU - Choi, Heun

AU - Choi, Youn Jeong

AU - Lee, Kyung Joo

AU - Lee, Seung Woo

AU - Han, Seung Hyuk

AU - Kim, Jin Seok

AU - Song, Si Young

PY - 2014/1

Y1 - 2014/1

N2 - Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

AB - Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

UR - http://www.scopus.com/inward/record.url?scp=84893052376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893052376&partnerID=8YFLogxK

U2 - 10.5009/gnl.2014.8.1.109

DO - 10.5009/gnl.2014.8.1.109

M3 - Article

C2 - 24516709

AN - SCOPUS:84893052376

SN - 1976-2283

VL - 8

SP - 109

EP - 112

JO - Gut and Liver

JF - Gut and Liver

IS - 1

ER -

Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: A case report and review of the literature

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this